Oncternal Therapeutics Inc To Discuss Strategic Reprioritization and Capital Preservation, Extends Cash Runway into 2025 Transcript
Greetings, and welcome to Oncternal analyst and investor call. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce your host Richard Vincent, Chief Financial Officer. Thank you. You may begin.
Thank you, [Doug]. Good afternoon, everyone, and thank you for joining us today. Joining me on the call this afternoon is our President and CEO, Dr. James Breitmeyer. This afternoon, we issued a press release describing a strategic reprioritization of our pipeline and cash preservation strategy. Today's press release and a replay of today's call will be available on the Investor Relations section of Oncternal's website for at least the next 30 days.
Please note that certain information discussed on today's call is covered under the Safe Harbor provisions of the Private Securities Litigation Reform Act. We will be making forward-looking statements during this call about future events, such as our business and product development strategies. The timing of
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |